NCT03728335 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03728335
Title	Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	City of Hope Medical Center
Indications	acute myeloid leukemia
Therapies	Enasidenib
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
City of Hope Medical Center	RECRUITING	Duarte	California	91010	United States	Details
Moffitt Cancer Center	SUSPENDED	Tampa	Florida	33612	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03728335Clinical Trial Detail